196 related articles for article (PubMed ID: 21779398)
1. Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation.
Seredenina T; Gokce O; Luthi-Carter R
PLoS One; 2011; 6(7):e22231. PubMed ID: 21779398
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.
Jovicic A; Zaldivar Jolissaint JF; Moser R; Silva Santos Mde F; Luthi-Carter R
PLoS One; 2013; 8(1):e54222. PubMed ID: 23349832
[TBL] [Abstract][Full Text] [Related]
3. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
[TBL] [Abstract][Full Text] [Related]
4. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
[TBL] [Abstract][Full Text] [Related]
5. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
6. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
7. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
[TBL] [Abstract][Full Text] [Related]
8. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
9. Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.
Bonda M; Perrin V; Vileno B; Runne H; Kretlow A; Forró L; Luthi-Carter R; Miller LM; Jeney S
Anal Chem; 2011 Oct; 83(20):7712-20. PubMed ID: 21888376
[TBL] [Abstract][Full Text] [Related]
10. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease.
Perrin V; Régulier E; Abbas-Terki T; Hassig R; Brouillet E; Aebischer P; Luthi-Carter R; Déglon N
Mol Ther; 2007 May; 15(5):903-11. PubMed ID: 17375066
[TBL] [Abstract][Full Text] [Related]
12. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS
Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599
[TBL] [Abstract][Full Text] [Related]
13. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
14. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
17. Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1.
Maglione V; Marchi P; Di Pardo A; Lingrell S; Horkey M; Tidmarsh E; Sipione S
J Neurosci; 2010 Mar; 30(11):4072-80. PubMed ID: 20237277
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.
Runne H; Régulier E; Kuhn A; Zala D; Gokce O; Perrin V; Sick B; Aebischer P; Déglon N; Luthi-Carter R
J Neurosci; 2008 Sep; 28(39):9723-31. PubMed ID: 18815258
[TBL] [Abstract][Full Text] [Related]
19. Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.
Desplats PA; Lambert JR; Thomas EA
Neurobiol Dis; 2008 Sep; 31(3):298-308. PubMed ID: 18595722
[TBL] [Abstract][Full Text] [Related]
20. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
